The impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia was evaluated in a retrospective cohort study conducted during population-based surveillance for invasive pneumococcal disease in the greater Atlanta region during 1994. Of the 192 study patients, 44 (23%) were infected with pneumococcal strains that demonstrated some degree of penicillin nonsusceptibility. Compared with patients infected with penicillin-susceptible pneumococcal strains, patients whose isolates were nonsusceptible had a significantly greater risk of in-hospital death due to pneumonia (relative risk [RR], 2.1; 95% confidence interval [CI], 1-4.3) and suppurative complications of infection (RR, 4.5; 95% CI, 1-19.3), although only risk of suppurative complications remained statistically significant after adjustment for baseline differences in severity of illness. Among adults with bacteremic pneumococcal pneumonia, infection with penicillin-nonsusceptible pneumococci is associated with an increased risk of adverse outcome.
proportion of resistant strains and their MICs continue to increase. Guidelines and recommendations for empirical therapy for patients with community-acquired pneumonia have already been modified to account for these resistance patterns [9] . The absence of a demonstrated correlation between pneumococcal drug resistance and adverse medical outcomes may reflect the predominance of isolates with only intermediate levels of penicillin resistance in prior studies. In addition, few studies of outcome have included patients whose isolates are resistant to the antimicrobial drugs that were used in their therapy (discordant therapy).
Recent work has highlighted the degree to which in vitro susceptibility results do not directly correlate with the predicted in vivo efficacy of antimicrobial drugs [10] . Another limitation of most studies has been the reliance on a single clinical outcome-death-to measure antimicrobial efficacy. However, mortality may be a relatively insensitive measure of antibiotic efficacy, given the historical finding that the rate of mortality associated with pneumococcal pneumonia during the first 72 h was relatively unaffected by the introduction of antimicrobial therapy [11] . Recent work has validated the use of additional in-hospital and postdischarge measures to evaluate other medical outcomes for patients with community-acquired pneumonia [12] [13] [14] .
The aim of this study was to compare medical outcomes, including in-hospital mortality, medical complication rates, and times to clinical stability, between patients with communityacquired pneumonia due to penicillin-susceptible strains of S. pneumoniae and those infected with penicillin-nonsusceptible strains. A secondary aim was to measure the frequency of discordant antimicrobial therapy among patients with penicillinnonsusceptible pneumococcal pneumonia.
Methods
Patients. Patients for this study were enrolled as part of a population-based surveillance of invasive infections due to S. pneumoniae within the metropolitan Atlanta region from January through October 1994. Details of this surveillance have been reported elsewhere [2, 15] . In brief, microbiology laboratories of 32 hospitals and 1 major reference laboratory in the 8-county metropolitan Atlanta area contributed pneumococcal isolates from normally sterile sites, including blood, CSF, and pleural fluid. Patients who had isolates recovered from these sites were considered to have invasive pneumococcal diseases. Laboratories provided demographic and limited clinical data on the patients.
Patients were excluded from the study if they resided outside the surveillance area, their place of residence was unknown, or the source of their isolate was unknown. This exclusion occurred before the collection of any medical-record data. Medical records were requested and subsequently abstracted for all hospitalized patients with invasive pneumococcal disease. For those patients whose medical records were not available, limited data could be obtained from the initial surveillance case report form, which allowed these excluded patients to be compared with the patients whose medical records were available.
We restricted analyses to adult patients (aged у18 years) with invasive pneumococcal disease whose medical records were available for review and who met criteria for diagnosis of bacteremic pneumococcal pneumonia. These criteria included findings on admission chest radiography consistent with pneumonia, including infiltrate, consolidation, or effusion. Patients whose CSF yielded S. pneumoniae were excluded. We restricted the analyses to patients aged у18 years because adult and pediatric pneumonia are etiologically distinct entities [16] associated with distinct management strategies (involving differences in hospitalization rates, for instance) and clinical outcomes (including differences in mortality rates). In addition, the pneumonia-specific severity models used for the analyses were developed and validated in adult populations only [17] [18] [19] . Finally, we excluded patients who did not have pneumonia diagnosed within 48 h of hospital admission. For this exclusion, we used the date of first administration of an antimicrobial drug as the date of diagnosis. Patients with pneumonia diagnosed after 48 h of hospitalization are more likely to have nosocomial pneumonia [14] .
Data collection. Baseline information on sociodemographic characteristics, initial severity of pneumonia, comorbid conditions, vital signs, laboratory results, and chest radiographic findings on admission were collected for all study subjects by use of a structured medical chart abstraction tool. Pneumonia severity was assessed by means of the Pneumonia Severity Index (PSI), a well-validated disease-severity classification based on age, sex, nursing home residence, 5 comorbid illnesses (neoplastic disease, liver disease, congestive heart failure, cerebrovascular disease, and renal disease), vital signs on admission, mental status, and 7 laboratory and radiographic values [19] . This index generates a score that can be used to classify patients into 5 risk classes, with 30-day observed mortality ranging from 0.1% for class I (lowest risk) to 27% for class V (highest risk).
Four variables from the original PSI were not available for this data analysis because they were not included during the original chart abstraction. These variables-presence of cerebrovascular disease, altered mental status, and blood glucose and blood urea nitrogen values at the time of admission-were omitted in the calculation, resulting in a modified PSI for this study. Stratification of patients into the original 5 risk classes with use of this modified PSI resulted in significant discrimination of disease severity, with observed in-hospital mortality rates of 3.7%, 4.4%, 9.4%, 22.9%, and 38.9% for patients in risk classes I-V, respectively (P = .001 for test of trend).
Assessment of medical outcomes was based on medical chart review. A standardized data collection form was used to abstract medical-record data on initial and subsequent antimicrobial chemotherapy, daily vital sign data, in-hospital complications and morbid events, in-hospital deaths, and time to hospital discharge. For daily vital signs, the highest temperature, heart rate, and respiratory rate and the lowest systolic blood pressure were abstracted from the medical chart for each of the first 7 days of hospitalization. In-hospital complications were recorded during the first 7 days of hospitalization and included admission to an intensive care unit, mechanical ventilation, and receipt of intravenous pressor agents (dopamine, dobutamine, norepinephrine bitartrate, and/or epinephrine). Additional suppurative complications of pneumococcal illness included empyema, lung abscess, and osteomyelitis.
Antimicrobial susceptibility testing was performed on all isolates by the broth-dilution method at the Centers for Disease Control and Prevention [20] . The susceptibility breakpoints for each drug were defined according to 1994 National Committee for Clinical Laboratory Standards (NCCLS) guidelines [21, 22] . The NCCLS has defined 3 separate categories of antimicrobial susceptibility: susceptible, intermediate (formerly called low-level resistance, corresponding to MICs of 0.1-1 mg/mL of penicillin), and resistant (formerly called high-level resistance, corresponding to MICs у2 mg/mL of penicillin) [21] . For the purposes of this article, penicillinintermediate or -resistant isolates are referred to as penicillinnonsusceptible.
Analysis. For all analyses, patients' pneumococcal isolates were categorized as penicillin-susceptible or -nonsusceptible, as described above. Baseline demographic, clinical, and laboratory variables were compared with x 2 , Fisher's exact, or Cochran-MantelHaenszel trend statistics, where appropriate, with use of 2-sided tests and a P value !.05 to indicate statistical significance [23] .
In-hospital mortality was determined for all study patients on the basis of the medical-records review. Pneumonia-related deaths were defined as those in which pneumonia was the major contributing cause according to the medical records; in those cases in which the cause was not clearly documented, death within 7 days following admission was also considered pneumonia-related. Deaths that did not appear to be pneumonia-related, as determined at the time of medical-record review, and occurred 17 days after admission were coded as non-pneumonia-related deaths. This mortality classification scheme is consistent with findings from prior studies on mortality associated with community-acquired pneumonia [24] . (27) 11 (25) .771 Coronary artery disease 13 (9) 5 (11) .567 Congestive heart failure 10 (7) 5 (11) .341 Renal disease 10 (7) 9 (20) .018 Hepatic disease 13 (9) 6 (14) .403 HIV infection d 43 (29) 11 (25) .599 Active cancer 19 (13) 9 (20) .209 Alcohol or drug abuse e 51 (41) 7 (19) .015
NOTE. Pen-NS, penicillin-nonsusceptible (MIC у0.1 mg/mL); Pen-S, penicillin-susceptible (MIC !0.1mg/mL).
a Patients for whom data were missing represented !5% of the study group for each variable, except alcohol/drug abuse (16%), and were excluded from denominator of relevant analyses. b Based on x 2 or Fisher's exact test (when expected counts were !5 per cell). c Includes chronic obstructive pulmonary disease, asthma, and restrictive/interstitial lung disease.
d HIV infection was documented in 28% of patients; those patients whose HIV status was not documented were assumed to be HIV-negative. e Includes documented alcohol, cocaine, or injection drug abuse.
Pneumonia-related mortality rates and medical complication rates were compared between patients with penicillin-susceptible and penicillin-nonsusceptible pneumococcal isolates. Unadjusted results were reported as RRs with 95% CIs. In additional analyses, adjustments were made for severity of illness at baseline by stratification according to the 5 levels of pneumonia severity, determined by means of the PSI. In these stratified analyses, the Mantel-Haenszel procedure was used to calculate common RRs, with adjustments for pneumonia-severity risk group [23] .
The time to resolution of individual vital sign abnormalities was defined as the first day that the highest or lowest value for the vital sign was within a predetermined normal range. For temperature, the maximum normal value was 37.2ЊC; for heart rate, the maximum normal value was 100 beats/min; for respiratory rate, the maximum normal value was 24 breaths/min; and for systolic blood pressure, the minimum normal value was 90 mm Hg. These cutoff points have been previously validated as measures of stability for patients recovering from community-acquired pneumonia. Validation was performed by demonstrating that among hospitalized patients with pneumonia, once vital signs had normalized, clinical deterioration requiring intensive care, coronary care, or telemetry was extremely rare [12] . The time to individual vital sign stability was calculated with the Kaplan-Meier product-limit method; logrank tests were used to compare times between patients with susceptible and nonsusceptible pneumococcal isolates [25, 26] .
In these analyses, only patients with a documented unstable vital sign during the first day of hospitalization were entered in each separate vital sign analysis. The overall time to vital sign stability was calculated on the basis of time to resolution of all 4 vital sign abnormalities, including those for all patients with at least 1 vital sign abnormality during the first day of hospitalization. All analyses were conducted with SAS for Windows (Release 6.12, SAS Institute, Cary, NC).
Finally, a descriptive analysis was completed to examine the concordance of initial empirical antibiotic therapy delivered within the first 48 h of hospitalization. Concordant therapy was defined as the receipt (during the first 48 h) of any antimicrobial agent that belonged to an antimicrobial drug class to which the isolate demonstrated full in vitro susceptibility. Conversely, if all antimicrobial drugs used to treat a patient during the first 48 h of hospitalization were within drug classes to which the pneumococcal isolate demonstrated any level of antimicrobial nonsusceptibility, the patient's therapy was classified as discordant.
Results
Patients' characteristics. During the surveillance period of this study (1 January 1994 through 31 October 1994), 527 patients with cases of invasive pneumococcal disease were identified in the source population of metropolitan Atlanta. Pneumococcal isolates for susceptibility testing and inpatient medical records for review were available for 296 patients (56%). Compared with the adult hospitalized patients without available medical records, the patients with available records were not significantly different in terms of sex, age, or overall mortality (data not shown). A total of 192 of the case patients with available medical records (65%) met study-eligibility criteria and thus are the study group for this study. The noneligible patients with medical records available for review and the eligible patients were similar with respect to sex and race/ethnicity. However, since an age of !18 years was an exclusion criterion, eligible patients had markedly increased frequency of comorbid illnesses associated with advanced age, including cardiovascular disease (20% vs. 8%, ). P = .013 The mean age of the study group was 53 years (range, 21-93 years); 47% were women; 47% were white, non-Hispanic; and 5% were admitted from nursing homes or chronic care facilities. HIV infection was documented in 28% of patients, and chronic pulmonary disease, including asthma and chronic obstructive pulmonary disease, was documented in 27% of patients.
Of the 192 study patients, 44 (23%) had documented infection with nonsusceptible pneumococci, 36 (19%) had intermediatesusceptible isolates, and 8 (4%) had resistant isolates. Compared with patients infected with susceptible strains, patients with nonsusceptible isolates were older (43% vs. 26% were у65 years;
), more likely to be white, non-Hispanic (63% vs. 42%; P = .03 ), less likely to be uninsured (14% vs. 31%; ), and P = .02 P = .02 more likely to be admitted from a nursing home (11% vs. 3%, ). The frequency of comorbid conditions in the suscep-P = .05 tible and nonsusceptible infection groups was similar, with the exception of renal disease, which was less frequent in the susceptible-infection group (7% vs. 20%; ), and alcohol/ P = .018 drug abuse, which was more frequent in the susceptible group (41% vs. 19%;
; In general, vital sign and laboratory abnormalities at the time of hospitalization were documented with similar frequency among patients with susceptible and nonsusceptible pneumococcal pneumonia (table 2) . However, on the basis of the PSI, which incorporates demographic, clinical, laboratory, and vital sign variables, patients with nonsusceptible pneumococcal infections had a higher severity of illness at admission than did patients with susceptible pneumococcal infections. For example, 46% of patients with nonsusceptible isolates were classified within the 2 highest severity-of-illness categories (risk classes IV and V), compared with 31% of patients with susceptible isolates ( for overall trend; table 2). P = .050 In-hospital mortality and morbidity.
Overall, in-hospital mortality associated with bacteremic pneumococcal pneumonia was 14%. Ten patients (23%) with penicillin-nonsusceptible pneumococcal pneumonia died, compared with 16 patients (11%) with penicillin susceptible pneumococcal pneumonia (RR, 2.1; 95% CI, 1.02-4.30). The increased rate of pneumoniarelated death was not statistically significant after adjustment for severity of illness at admission. Similar rates of respiratory failure, shock, and admission to an intensive care unit were noted in the 2 groups. In contrast, the risk of suppurative complications was 14-fold greater among patients with nonsusceptible pneumococcal isolates than among patients with susceptible isolates (RR, 4.5; 95% CI, 1.04-19.3).
All of the patients with nonsusceptible isolates and suppurative complications had documented empyemas, and 1 patient had both an empyema and a lung abscess. Even after adjustment for differences in severity of illness at admission, patients with nonsusceptible pneumococcal infections had a significantly higher rate of suppurative complications than did patients with susceptible pneumococcal infections (RR, 4.8; 95% CI, 1.2-18.8; table 3). In addition, adjustment of these analyses for pneumococcal serotype did not change the association between penicillin nonsusceptibility and increased risk of suppurative complications (data not shown).
Among the subgroup of patients with documented HIV infection, the RR for pneumonia-related death was 11.7 (95% CI, 1.3-102.1) comparing patients infected with penicillin-nonsusceptible versus penicillin-susceptible S. pneumoniae. Among patients without documented HIV infection, the RR for death was only 1.5 (95% CI, .6-3.3). Similar associations were not observed for the other measured clinical outcomes. The small size of these subgroups did not permit further adjustment of these data for differences in severity of illness at admission.
Time to clinical stability. For each vital sign, similar proportions of patients in each group were identified as unstable during the first day of hospitalization. Among patients with a temperature 137.2ЊC during the first hospital day, the median time to stability (temperature, р37.2ЊC) was 4 days for patients with susceptible isolates and 3 days for patients with nonsusceptible isolates ( ). Among patients with respiratory P = .16 rates 124 breaths/min, the time to stabilization of the respiratory rate was 3 days for patients with susceptible isolates and 2 days for patients with nonsusceptible isolates ( ). P = .62 Among patients with abnormal heart rates or systolic blood pressure, median times to stability were essentially equivalent between the 2 patient groups. The overall time to vital sign stability was 4 days for the patients with nonsusceptible isolates and 5 days for those with susceptible isolates ( , log-rank P = .55 test). Among all patients, clinically significant worsening of vital signs after normalization was rare; this occurred in 1%-6% of patients, depending on the particular vital sign examined (data not shown).
Concordance of antimicrobial therapy. To better explain the impact of antimicrobial susceptibility on medical outcomes, we examined the concordance of antimicrobial therapy administered within the first 48 h of hospitalization among patients with penicillin-nonsusceptible pneumococcal pneumonia. At each level of penicillin nonsusceptibility, the majority of patients received at least 1 antimicrobial drug to which their pneumococcal isolate was susceptible. For example, among patients with pneumococcal isolates displaying intermediate penicillin susceptibility (MIC, 0.1-1 mg/mL), 31 of 36 received at least 1 concordant antimicrobial drug within the first 48 h of hospitalization. Of 8 patients infected with penicillin-resistant pneumococcal isolates (MIC, у2 mg/mL), 4 were classified as receiving concordant antimicrobial therapy, including 2 who received vancomycin within 48 h and 2 additional patients who received macrolides or cephalosporins with preserved antipneumococcal activity.
Overall, 80% of patients with penicillin-nonsusceptible pneumococcal infections received concordant antimicrobial therapy within 48 h of hospitalization (table 4). This result was identical if the time frame was limited to the first 24 h of hospitalization, reflecting the infrequency of changes in antimicrobial therapy during the first 48 h of hospitalization (data not shown). In a comparison of patients receiving concordant therapy with patients receiving discordant antimicrobial therapy, there were no significant differences in rates of in-hospital death (14% vs. 11%; ) or suppurative complications (4% vs. 0%; ). P = 1.0 P = 1.0
Discussion
In this population-based study of adult patients with bacteremic pneumococcal pneumonia, patients infected with penicillin-nonsusceptible strains of pneumococci had a greater average severity of illness at admission than did patients infected with susceptible strains. Severity of illness was based on a previously validated, multivariable predictive model of short-term pneumonia-specific mortality [19, 27] . Although patients infected with nonsusceptible pneumococcal isolates had an increased risk of in-hospital mortality, this difference was not statistically significant after adjustment for differences in severity of illness at presentation. Patients with penicillin-nonsusceptible pneumococcal isolates had a greater risk of suppurative complications than did patients with susceptible isolates, even after adjustment for differences in severity of illness.
Finally, data on initial empirical antimicrobial drug therapy show that the majority of patients with nonsusceptible isolates actually received concordant antimicrobial therapy. Among the small group of patients with penicillin nonsusceptible isolates receiving discordant antimicrobial therapy, medical outcomes were not measurably worse than those for patients receiving concordant therapy.
Medical outcomes for patients with community-acquired pneumococcal pneumonia reflect at least 3 factors associated with the antimicrobial susceptibility of the bacterial isolate. The first factor to consider is the concordance (or discordance) of the antimicrobial drug therapy received by the patients, in relation to the in vitro susceptibility profile of the pneumococcal isolate. It seems obvious that antimicrobial drug resistance can lead to adverse medical outcomes only if it is reflected in the use of antimicrobial therapies to which the bacteria are resistant. For example, for patients infected with penicillin-nonsusceptible pneumococci, adverse medical outcomes attributed to the drug resistance are less likely if they are empirically treated with quinolones and cephalosporins with preserved activity against the isolates. Indeed, once culture and susceptibility results are reported, few clinicians are likely to maintain administration of antimicrobial drugs to which the pneumococcal isolate is reported to be nonsusceptible; therefore virtually all patients are likely to receive concordant antimicrobial drug therapy within a few days of hospitalization. Thus, investigators performing observational studies will need to rely on the impact of empirical antimicrobial drug therapy in assessing the impact of antimicrobial drug resistance. However, these studies will be difficult to conduct if multiple drugs are given with initial therapy or if initial therapy routinely includes newly licensed broad-spectrum antimicrobial drugs.
Our analysis of the impact of antimicrobial drug selection on medical outcomes was conservative in that we considered therapy to be discordant if all of the administered antimicrobial agents belonged to drug classes with intermediate or resistant susceptibility profiles in vitro. For example, administration of penicillin drugs was considered discordant therapy for patients infected with pneumococci with any degree of penicillin nonsusceptibility (including intermediate susceptibility to penicillin). However, studies with animal infection models have shown that antimicrobial concentrations that do not exceed the MIC for 100% of the dosing interval can still have a significant antibacterial effect.
For most b-lactams, a concentration above the MIC for 140% of the dosing interval is sufficient to achieve bacteriologic cure rates approaching 100% [10] . Furthermore, standard parenteral doses of ampicillin, penicillin, cefotaxime, and ceftriaxone achieve concentrations above the MIC for у40% of the dosing interval for pneumococci even with high levels of resistance (up to 4 mg/mL for penicillin resistance and 2 mg/mL for ceftriaxone resistance). The implication of this model is that virtually all patients in our study received antimicrobial therapy that was theoretically concordant with the susceptibility of their isolates; therefore our study was significantly underpowered to measure the impact of antimicrobial resistance on medical outcomes.
A second factor to consider in evaluating the impact of antimicrobial resistance on medical outcomes is severity of illness at the time of diagnosis. Several studies have established that a number of clinical and demographic factors increase risk for infection with nonsusceptible vs. susceptible pneumococcal strains, including advanced age and underlying comorbid illnesses [15, [28] [29] [30] . Some of these factors, particularly advanced age, have also been shown to be independent risk factors for poor outcomes for patients with community-acquired pneumonia. Thus it is not surprising that substantial confounding exists in the analysis of medical outcomes for patients infected with pneumococci of varying degrees of antimicrobial susceptibility.
The PSI is a well-validated pneumonia-specific severity-ofillness measure that permits adjusted comparisons of medical outcomes among patients infected with susceptible and nonsusceptible pneumococci. In support of our findings, Pallares et al. reported that differences in medical outcomes between patients infected with susceptible and nonsusceptible pneumococci did not remain statistically significant in multivariate analyses adjusting for differences in severity of illness [6] .
A third factor to be considered in comparing medical outcomes between patients infected with susceptible and nonsusceptible pneumococci is the potential relationship between antimicrobial susceptibility and bacterial virulence. It is generally assumed that pneumococci with reduced penicillin susceptibility are no more or less virulent than their penicillin-susceptible counterparts [31] . However, this conclusion is largely untested in clinical studies with adequate sample size to adjust for critical confounding host factors. It has been hypothesized that acquiring resistance genotypes may result in a cost to the organism in terms of transmissibility or virulence [32] .
The impact of virulence on medical outcomes may be ap-parent for outcomes other than death. However, in our study, the time to improvement of abnormal vital signs was not significantly different among patients with susceptible versus nonsusceptible isolates. Future studies of medical outcomes among patients infected with susceptible and nonsusceptible pneumococcal isolates should similarly include sensitive outcome measures, such as time to vital sign improvement, in order to further explore the relationship of antimicrobial susceptibility and bacterial virulence. Rates of medical outcomes for patients in this study were consistent with prior findings of outcome research concerning patients with community-acquired pneumonia. In a recent meta-analysis of studies examining prognoses for patients with pneumonia, the case-fatality rate among patients with pneumococcal pneumonia was 12.3%, ranging from 8.3% among all hospitalized patients to as high as 18% among hospitalized patients with pneumococcal bacteremia [33] . The overall casefatality rate in this study was 14%. In addition, the times to stabilization of individual vital sign abnormalities were nearly identical to those reported following a recent study of hospitalized patients with community-acquired pneumonia [12] .
HIV infection was documented in a substantial proportion (28%) of patients with bacteremic pneumococcal pneumonia in this study. Indeed, this proportion may be an underestimate because we assumed that patients without medical-record documentation of HIV infection were HIV-uninfected. Prior work has demonstrated that HIV-infected patients are at a significantly higher risk of developing bacteremic pneumococcal pneumonia than is the general population [34] [35] [36] . However, in this study, HIV infection was not a risk factor for infection with a penicillin-nonsusceptible isolate (table 1) .
Moreover, in the total study group, HIV infection was not associated with any of the study outcomes, including death and suppurative complications, in both univariate and multivariate analyses. It is noteworthy that penicillin nonsusceptibility was much more strongly associated with pneumonia-related mortality among HIV-infected patients than among HIV-uninfected patients, but we were unable to further adjust these results for differences in severity of illness at admission. Other investigators have similarly reported that among HIV-infected populations with pneumococcal pneumonia, penicillin resistance may be an important independent predictor of mortality [37] .
Some limitations of this study should be noted. First, we limited this study to medical outcomes observed during hospitalization. While the majority of serious medical complications of pneumonia are likely to occur in the hospital, for many patients the variations in medical outcomes are more apparent for postdischarge events, such as the time until return to work and resolution of symptoms [13] . Future research should examine both hospital and postdischarge outcomes.
In addition, we did not report on differences in the processes and resulting costs of care between patients with penicillinsusceptible and penicillin-nonsusceptible pneumococcal pneumonia. Such data should be included in future studies in order to allow a full evaluation of the impact of antimicrobial susceptibility on the care of patients with this condition.
Another potential limitation relates to the generalizability of these results. The surveillance system used for this study focused on invasive pneumococcal disease and thus did not include the larger population of patients with nonbacteremic pneumococcal pneumonia. However, definitive identification of pathogens in nonbacteremic patients with community-acquired pneumonia remains problematic. As we did not include children or outpatients with pneumococcal disease in the study sample, our results may not be applicable to those populations. We also excluded some adult hospitalized case patients from the analysis because isolates were not available for susceptibility testing or records were not available for review.
On the basis of very limited data, these excluded patients do not appear significantly different from the included patients; therefore, our results may be generalizable for the population of adults hospitalized with invasive pneumococcal pneumonia. In addition, as discussed earlier, the overall outcomes observed in this study are consistent with those in prior studies of patients with pneumococcal pneumonia.
Finally, patients for this study were identified in 1994, when the proportion of nonsusceptible isolates demonstrating highlevel penicillin resistance was lower than it is currently. Moreover, the number of patients receiving discordant therapy was extremely small, reflecting the small number of highly resistant isolates as well as the common practice of prescribing broadspectrum antimicrobial agents in the empirical treatment of patients with pneumonia. Thus this study was underpowered to detect clinically important adverse effects of antimicrobial resistance on medical outcomes among patients receiving standard first-line agents such as b-lactam drugs.
Recent studies have documented an increase in the prevalence of strains with higher MICs of penicillin and multidrug resistance [5] . Future studies may be sufficiently powered to detect adverse outcomes for patients who are infected with pneumococci demonstrating higher levels and more complex patterns of drug resistance and, therefore, a greater frequency of discordant antimicrobial therapy. However, if clinicians continue to switch empirically administered drugs to newer agents, even in settings where the use of older agents has not been shown to produce clinical failures, it will remain difficult to identify sufficient cases of discordant therapy to evaluate the true clinical impact of these therapies.
In conclusion, it is important that we improve our understanding of the impact of patterns of antimicrobial susceptibility on medical outcomes for patients with pneumococcal pneumonia so that we can better guide antimicrobial therapy for these patients. In an era of rapidly emerging antimicrobial resistance, clinicians must balance the benefits of selecting broader-spectrum antimicrobial drugs for these patients against the risks of inducing even more complex patterns of antimi-crobial drug resistance. In order to preserve the effectiveness of broader-spectrum antimicrobial agents, we need to identify clinical situations in which the use of conventional drug therapy will lead to adverse medical outcomes.
Future research on the impact of antimicrobial drug resistance on medical outcomes for patients with pneumococcal pneumonia should emphasize the concordance of drug therapy, should control for differences in baseline severity of illness, and should examine multiple medical outcomes beyond the period of hospitalization.
